TGFB1 and obesity due to melanocortin 4 receptor deficiency: A better understanding of the pathways involved in poor cancer outcomes due to obesity will allow us to use rational combinations of agents such as TGFB1 antagonists, anti-estrogens, and metformin for improving outcomes in obese breast cancer patients.